
- Insmed (INSM) is a biopharmaceutical company with strong momentum.
- Shares are trading at new 20-year highs.
- INSM has surged 128% over the past year.
- Analysts expect robust revenue and earnings growth, but opinions are mixed, with some cautioning the stock is overvalued.